Genomic Medicine · us
After Otarmeni’s Approval, Treatment for Hereditary Hearing Loss Enters a “Genetic Diagnosis First” Stage
After Otarmeni became the first approved gene therapy for OTOF-related hereditary hearing loss, the focus has shifted to clinical implementation: which patients can benefit, how mutation types should be confirmed, and whether early hearing improvements can be maintained over a longer period.
The U.S. FDA has approved Regeneron’s Otarmeni, providing the first approved gene therapy for hereditary hearing loss related to the OTOF gene. The decision itself is an important milestone for rare disease treatment; the more critical question now is how this type of therapy will move from trial settings into routine clinical care.
Otarmeni targets severe to profound sensorineural hearing loss caused by mutations in the OTOF gene. OTOF is responsible for producing the otoferlin protein, which helps inner-ear hair cells convert sound vibrations into nerve signals; if the gene copies a patient inherits from both parents are damaged, signal transmission between the inner ear and the brain is severely disrupted.
The therapy is given as a one-time treatment, using a viral vector to deliver a functional OTOF gene into cells in the ear. According to published trial data, 16 of 20 participants showed hearing improvement within six months, and another 1 showed improvement within one year; in some responders, hearing improved to the point that they could hear soft speech.
However, these data still require cautious interpretation. The trial was small, follow-up time was limited, and the publicly available information is currently insufficient to fully answer questions such as how long efficacy can be maintained, whether patients of different ages or at different disease stages benefit similarly, and what the long-term safety profile will be. For rare genetic diseases, post-marketing follow-up is usually central to assessing a therapy’s true value.
Otarmeni also does not mean that all congenital or childhood hearing loss can be treated with gene therapy. Hereditary hearing loss involves multiple genes and different biological mechanisms, and OTOF is only one category; therefore, genetic testing and precise diagnosis will become prerequisites for treatment. Without confirming the cause of disease, it is difficult to determine whether a patient fits the mechanism of this type of therapy.
**Background Context**
From a broader perspective, Otarmeni’s approval moves inner-ear gene therapy from proof of concept toward regulatory recognition, but it also highlights a common dilemma in rare disease therapies: early results are promising, while evidence accumulation takes time. For clinical practice, the real test will be integrating genetic diagnosis, treatment timing, and long-term follow-up into the care pathway.
For patient families and clinicians, the most practical change in the short term may not be the immediate replacement of existing options such as cochlear implants, but rather the addition of another treatment pathway for some patients clearly carrying OTOF mutations. If more gene therapies for hearing loss enter review in the future, Otarmeni’s follow-up results will become an important reference for evaluating the feasibility of this field.